CorMedix Inc.
CRMD
CRMD: Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The Company's primary focus is to develop its lead product candidate, DefenCath, for potential commercialization in the United States (U.S.) and other key markets.
moreShow CRMD Financials
Recent trades of CRMD by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by CRMD's directors and management
Government lobbying spending instances
-
$50,000 Jul 20, 2023 Issue: Health Issues
-
$30,000 Jul 14, 2023 Issue: Medicare/Medicaid
-
$10,000 Oct 17, 2018 Issue: Health Issues
-
$20,000 Apr 19, 2018 Issue: Health Issues
-
$30,000 Jan 19, 2018 Issue: Health Issues
-
$30,000 Oct 17, 2017 Issue: Health Issues
-
$30,000 Jul 19, 2017 Issue: Health Issues
-
$30,000 Apr 20, 2017 Issue: Health Issues
-
$30,000 Jan 23, 2017 Issue: Health Issues
-
$30,000 Oct 20, 2016 Issue: Health Issues
-
$30,000 Jul 20, 2016 Issue: Health Issues
-
$30,000 Apr 20, 2016 Issue: Health Issues
-
$30,000 Jan 20, 2016 Issue: Health Issues
-
$30,000 Oct 20, 2015 Issue: Health Issues
New patents grants
-
Patent Title: Synthesis of taurolidine, purity profiles and polymorphs Aug. 29, 2023
-
Patent Title: Neuroblastoma treatment with taurolidine hydrolysis products Jan. 03, 2023
-
Patent Title: Antimicrobial wound closure materials, including antimicrobial sutures, and method for closing a wound using the same Dec. 31, 2019
-
Patent Title: Field sterilizer and vascular connector kit Nov. 19, 2019
Federal grants, loans, and purchases
Followers on CRMD's company Twitter account
Number of mentions of CRMD in WallStreetBets Daily Discussion
Recent insights relating to CRMD
Recent picks made for CRMD stock on CNBC
ETFs with the largest estimated holdings in CRMD
Flights by private jets registered to CRMD